Surmodics, Inc.
SRDX · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $126 | $133 | $100 | $105 |
| % Growth | -4.9% | 32.6% | -4.9% | – |
| Cost of Goods Sold | $33 | $72 | $71 | $64 |
| Gross Profit | $93 | $61 | $29 | $41 |
| % Margin | 73.8% | 46% | 29% | 39.2% |
| R&D Expenses | $10 | $10 | $9 | $47 |
| G&A Expenses | $0 | $0 | $47 | $31 |
| SG&A Expenses | $57 | $52 | $47 | $31 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $32 | $41 | -$5 | $3 |
| Operating Expenses | $99 | $102 | $51 | $81 |
| Operating Income | -$6 | $5 | -$22 | $7 |
| % Margin | -4.5% | 3.9% | -22.1% | 6.4% |
| Other Income/Exp. Net | -$2 | -$3 | -$0 | -$0 |
| Pre-Tax Income | -$8 | $2 | -$22 | $6 |
| Tax Expense | $4 | $4 | $5 | $2 |
| Net Income | -$12 | -$2 | -$27 | $4 |
| % Margin | -9.2% | -1.2% | -27.3% | 4% |
| EPS | -0.82 | -0.11 | -1.96 | 0.31 |
| % Growth | -645.5% | 94.4% | -732.3% | – |
| EPS Diluted | -0.82 | -0.11 | -1.96 | 0.3 |
| Weighted Avg Shares Out | 14 | 14 | 14 | 14 |
| Weighted Avg Shares Out Dil | 14 | 14 | 14 | 14 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $4 | $3 | $1 | $0 |
| Depreciation & Amortization | $9 | $9 | $10 | $8 |
| EBITDA | $5 | $15 | -$12 | $15 |
| % Margin | 3.8% | 11.4% | -12.2% | 14% |